Association study between the neurexin-1 gene and tardive dyskinesia

Rachel Lanning, Tristram A. Lett, Arun K. Tiwari, Eva J. Brandl, Vincenzo de Luca, Aristotle N. Voineskos, Steven G. Potkin, Jeffrey A. Lieberman, Herbert Y. Meltzer, Daniel J. Müller, Gary Remington, James L. Kennedy*, Clement C. Zai

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Objective: Tardive dyskinesia (TD) is a motor side effect that may develop after long-term antipsychotic treatment. Schizophrenia has recently been associated with the Neurexin-1 (NRXN1) gene that codes for a cell adhesion molecule in synaptic communication. Methods: This study examined five NRXN1 single-nucleotide polymorphisms (SNPs) for possible association with the occurrence and severity of TD in 178 schizophrenia patients of European ancestry. Results: We did not find these SNPs to be significantly associated with TD. Conclusions: More research is needed with additional SNPs and in bigger samples before we can completely rule out the role of NRXN1 in TD.

Original languageEnglish (US)
Article numbere2568
JournalHuman Psychopharmacology
Issue number1
StatePublished - Jan 1 2017


  • antipsychotics
  • neurexin-1 (NRXN1)
  • pharmacogenetic
  • schizophrenia (SCZ)
  • tardive dyskinesia (TD)

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Association study between the neurexin-1 gene and tardive dyskinesia'. Together they form a unique fingerprint.

Cite this